Doxorubicin vs epirubicin, report of a second.line randomized phase 11/111 study in advanced breast cancer
1998

Comparing Doxorubicin and Epirubicin for Advanced Breast Cancer

Sample size: 232 publication Evidence: moderate

Author Information

Author(s): M Bontenbal, M Andersson, J Wildiers, G Cocconi, J Jassem, R Paridaens, N Rotmensz, R Sylvester, HT Mouridsen, JGM Klijn, AT van Oosterom

Primary Institution: EORTC Breast Cancer Cooperative Group

Hypothesis

Is epirubicin less toxic and equally effective as doxorubicin in treating metastatic breast cancer?

Conclusion

Doxorubicin showed a slightly longer duration of response and time to progression, but was more toxic than epirubicin.

Supporting Evidence

  • The overall response rates for doxorubicin and epirubicin were 36% and 28%, respectively.
  • The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin.
  • The median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin.
  • Doxorubicin was associated with significantly worse toxicity, including mucositis and diarrhoea.

Takeaway

This study looked at two medicines for breast cancer and found that one worked a bit better but was also more harmful.

Methodology

A randomized trial comparing doxorubicin and epirubicin in patients with metastatic breast cancer.

Limitations

The study was limited by the small difference in response rates and the need for treatment to be stopped after a cumulative dose.

Participant Demographics

Median age was 56 years, with a mix of performance statuses and prior treatments.

Statistical Information

P-Value

P = 0.173 for response rates, P = 0.063 for time to progression, P = 0.059 for duration of response.

Confidence Interval

95% CI 28-45% for doxorubicin response rate, 95% CI 20-36% for epirubicin response rate.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication